Quickly identifying genetic mutations in acute myeloid leukemia using advanced sequencing techniques
Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing
['FUNDING_R21'] · FRED HUTCHINSON CANCER CENTER · NIH-10815759
This study is testing a new, faster way to find genetic changes in acute myeloid leukemia (AML) to help doctors quickly understand how serious the disease is and choose the best treatment for patients.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10815759 on ClinicalTrials.gov |
What this research studies
This research focuses on improving the detection of genetic mutations and fusions in acute myeloid leukemia (AML) using a novel CRISPR-based sequencing method. By employing a single molecule long-read sequencing assay, the study aims to provide rapid results that can help in the timely stratification of patient risk and selection of appropriate treatments. The approach seeks to overcome limitations of traditional sequencing methods, allowing for same-day results that could significantly enhance patient care. The research will evaluate the effectiveness of this new method in identifying mutations and assessing tumor burden compared to existing techniques.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who require genetic profiling for treatment decisions.
Not a fit: Patients with other types of leukemia or those who do not have genetic mutations relevant to the study may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to faster and more accurate diagnosis and treatment selection for patients with acute myeloid leukemia.
How similar studies have performed: Other research has shown promise in using advanced sequencing techniques for cancer diagnosis, suggesting that this approach could be a significant advancement in the field.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YEUNG, CECILIA C — FRED HUTCHINSON CANCER CENTER
- Study coordinator: YEUNG, CECILIA C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.